Antihypertensive drugs may have an important effect on glomerular haemodynamics. In chronic nephropathy patients, we compared the effect on glomerular haemodynamics of two second-generation dihydropyridinic agents, nitrendipine and amlodipine, with a first generation dihydropyridinic agent and an ACE-inhibitor, enalapril. In all, 32 patients (pts), divided into four groups, received the different drugs: ENA (enalapril, eight pts), NIF (nifedipine, eight pts), NIT (nitrendipine, eight pts) AML (amlodipine, eight pts). The study assessed the effect on glomerular haemodynamics of a single administration of the test drug in baseline conditions and in glomerular hyperfiltration experimentally induced by amino-acid infusion. The glomerular filtration rate (GFR, measured by inulin clearance), effective renal plasma flow (ERPF, measured by p-aminohippurate clearance), renal vascular resistances (RVR) and filtration fraction (FF) were assessed. Administration of AML and NIT test dose reduced FF, as did ENA, but not NIF, in both baseline (AML: P ¼ 0.005; NIT: P ¼ 0.02; ENA: P ¼ 0.007) and glomerular hyperfiltration conditions (AML: P ¼ 0.0003; NIT: P ¼ 0.03; ENA: P ¼ 0.00006). In baseline conditions, only ENA resulted in a significant drop in the GFR (P ¼ 0.008), while NIF, NIT and AML induced a significant increase (P ¼ 0.003, 0.03, 0.0001, respectively). However, in hyperfiltration conditions, NIT (0.08) and AML (0.00003) caused a decrease in the GFR, as did ENA (0.0003) but not NIF. In all the experimental conditions, a RVR reduction and an ERPF increase were observed. Single dose of NIT and AML were effective in attenuating the effect of amino-acid infusion on glomerular filtration, similar to ENA; this effect of NIT and AML on the glomerular filtration rate is not observed under basal conditions.
Introduction
Reduced glomerular capillary pressure protects against the onset and progression of renal injury; [1] [2] [3] it is well known that this pressure is affected by the afferent and efferent arteriolar resistances. Any substance that not only reduces systemic vascular resistances, but also induces preferential dilatation of the efferent arteriole, could thus cause a reduction in glomerular capillary pressure and in the incidence of glomerular sclerosis. 4, 5 The theory that glomerular hypertension has a fundamental role in the progression of renal injury justifies the continuing search for treatment regimens that may succeed in reducing this hypertension. Assuming that in humans with chronic kidney disease, the onset of glomerular hypertension in the nephrons of the residual renal parenchyma might predispose toward progression of renal damage, antihypertensive drugs could exert an important effect on the glomerular haemodynamics of nephrons spared by the initial pathogenic noxae. It is well known that inhibitors of the angiotensin conversion enzymes (ACEi) such as enalapril (ENA) can slow the progression of the renal damage by reducing efferent arteriolar resistances and intraglomerular pressure. [6] [7] [8] [9] The angiotensin II receptor antagonists seem to share similar renal protection effects with the ACEi. 10, 15 On the contrary, first-generation dihydropyridinic calcium antagonists like nifedipine (NIF) do not have any marked vasodilatory effect on the efferent arteriole, do not reduce glomerular pressure and seem to have less protective effects on the kidney than the ACEi. [12] [13] [14] [15] Instead, there is some controversy as to the intrarenal haemodynamic effects of second generation dihydropyridinic calcium antagonists, as their vasodilatory effect on the efferent arteriole may vary according to the drug used. [16] [17] [18] [19] [20] [21] [22] [23] [24] In particular, the results of some studies suggest that amlodipine (AML) does not significantly reduce postglomerular resistances, 20, [22] [23] [24] whereas others have shown that amlodipine, nitrendipine (NIT) and other second-generation dihydropyridinic calcium antagonists induce haemodynamic variations suggesting a mainly efferent vasodilatory effect. [16] [17] [18] [19] 21 Unfortunately, as the method is highly complex, it has only been possible to carry out studies of the intrarenal haemodynamic effects of antihypertensive drugs on relatively small patient samples, and the assumption that calcium antagonists in general have only limited efficacy in reducing glomerular hyperfiltration has remained strong.
In order to assess how effective second-generation dihydropyridinic calcium antagonists really are in reducing glomerular hyperfiltration, we compared the intrarenal haemodynamic effects of a single dose of two such drugs, AML and NIT, with those of a single dose of an ACEi, ENA and of a first generation calcium antagonist, NIF. The comparison was conducted in a group of patients with chronic renal disease, mildly impaired renal function and mild-tomoderate arterial hypertension. The effects of the drugs on renal haemodynamics were assessed in baseline conditions and in transitory glomerular hyperfiltration conditions experimentally induced by the infusion of amino acids.
Patients and methods

Patients
A total of 32 patients (19 M and 13 F), mean age 45.6 7 3.4 years, with chronic kidney disease (16 patients with IgAN and 16 with interstitial nephritis) were studied. They were divided into four groups of eight patients, and the patients in each group were administered a single dose of a different drug:
* ENA group (enalapril 20 mg os), * NIF group (nifedipine R 20 mg os), * NIT group (nitrendipine 20 mg os), * AML group (amlodipine 10 mg os).
Patients assignment was random, but such as to enable an equal distribution of the two kidney diseases (four IgAN and four interstitial nephritis) in each group. The patients in the four groups were matched for sex, age, type of renal disease and creatinine clearance. At least 2 weeks before and for the entire duration of the study, all other medications were suspended and patients were given a protein intake ranging between 1.0 and 1.3 g/kg b.w./ day and a sodium intake of 200 mmol/day. This dietary restriction was adopted in order to exclude any influence on renal haemodynamics of a different protein and salt intake among patients. Compliance to the dietary prescriptions was ascertained on the basis of their nitrogen intake and sodium urinary excretion. The nitrogen intake was measured by calculating the urinary urea nitrogen in 24 h urine collection and the estimated nonurea nitrogen excretion of 29 mg/kg N kg À1 on alternate days, as follows: (urinary urea nitrogen+nonurinary urea nitrogen) Â 6.25. 25 This policy was adopted to ensure that the baseline value of the glomerular filtration rate (GFR) would reflect the patients' constant dietary habits (the so-called 'resting' GFR). [25] [26] [27] [28] The patient characteristics of each group are listed in Table 1 : there were no significant differences among the four groups for any parameter considered. The nature, purpose and potential risks of the study were explained to all subjects and informed consent was obtained prior to enrolment. The procedures followed were in accordance with the principles of the Declaration of Helsinki.
Study of intrarenal haemodynamics
Four haemodynamic parameters were considered, two of which were measured and two calculated. The two measured were the GFR and the effective renal plasma flow (ERPF); the two calculated were the 29 and performed using a Lifecare microinfuser (Pump model 4, Abbott Laboratories, North Chicago, IL 60064, USA); (c) collection of blood and urine samples to determine three consecutive clearances for both inulin and PAH, each measured over 30 min, so that each parameter value was obtained from the mean of three tests. Blood and urine collection was started after the period required to achieve stable plasma concentrations of inulin and PAH, at times +75, +105 and +135 min (blood samples and blood pressure measurement) and at times +90, +120 and +150 min (urine samples). The urinary volumes collected were replaced with an equal volume of oral water to maintain the hydration state unchanged. Inulin and PAH were assayed with a colorimetric method using diphenylamine and ethylenediamine-N-1-naphthyl chlorhydrate, respectively. 30 The RVR and FF were calculated from the measurements of the GFR and ERPF. The RVR was calculated, following Gomez's formula, as the ratio between mean blood pressure and effective renal blood flow (ERBF) Â 80 000 and expressed in dyn s cm
À5
. ERBF was determined as ERPF/1-haematocrit. Finally, the FF was obtained from the GFR/ERPF ratio.
Study design
In the four groups: ENA, NIF, NIT and AML, the GFR, ERPF, RVR and FF were assessed in four different experimental conditions:
* before administration of the test drug; * after administration of the antihypertensive test drug, to assess its effects of renal haemodynamics; the drug was administered at variable times before the clearance session according to its pharmocodynamic characteristics; as ENA reaches its peak serum concentration after 3-4 h it was administered (20 mg) 90 min before continuous infusion of inulin and PAH; NIF (20 mg) and NIT (20 mg) reach their peak serum concentration after 2-3 h, 31, 32 and were administered 60 min before the session; AML (10 mg) was administered 360 min before, as the peak is reached after about 6 h; 33 * during infusion of an amino-acid solution inducing glomerular hyperfiltration; the amino acids (Parentamin 10%, Pharmacia, a mixture of essential and nonessential amino acids) were infused after 30 min from the start of the continuous infusion of inulin and PAH, with a Lifecare Microinfuser at the rate of 6 mg/kg/min; * after administration of the test drug during amino-acid infusion.
The four experimental conditions were investigated in each patient at intervals of 48 h to restore the starting haemodynamic conditions. Figure 1 shows a diagram of the study design.
Finally, from the day before the first clearance session until the third day after conclusion of the study, antibacterial prophylaxis with 500 mg/day ciprofloxacin was given to avoid the risk of urinary infection from the bladder catheterization. Urine cultures performed on the 4th, 7th and 14th days after the end of the study gave negative results.
Statistical analysis
All variables were normally distributed and data were expressed in the text as mean 7 standard deviation (s.d.). Statistical comparison between groups was performed by paired t-test and one-way ANOVA. The data were analysed by SPSS Statistical Software.
Results
The mean values for the GFR are shown in Figure 2 . In baseline conditions (2a), the GFR (ml/min) was significantly reduced after administration of ENA (110.8 7 13.5 vs 79.8 7 22.2; P ¼ 0.0087), while it significantly increased after NIF (78.1 7 25.2 vs 106.2 7 27.9; P ¼ 0.003), NIT (76.8 7 24.4 vs 96.0 7 39.0; P ¼ 0.038) and AML (86.1 7 22.7 vs 103.6 7 27.3; P ¼ 0.0001). Instead, in the glomerular hyperfiltration conditions induced by amino-acid infusion (2b), the reduction in the GFR produced by AML (from 112.8 7 28.2 to 102.7 7 30.0; Figure 1 Design study scheme. PAH ¼ p-aminohippurate.
Calcium antagonist and glomerular pressure LF Morrone et al P ¼ 0.00003) and NIT (from 112.4 7 30.0 to 96.7 7 38.1; P ¼ 0.08 NS.) was similar to that of ENA (from 147.2 7 17.1 to 107.5 7 9.2; P ¼ 0.0003), while on the contrary NIF induced an increase in the GFR (from 107.9 7 20.0 to 129.9 7 32.7; P ¼ 0.04).
The effect of the drugs studied on the ERPF (ml/ min) is shown in Figure 3 , in baseline conditions (3a) and after amino-acid infusion (3b). All the drugs induced an increase in the ERPF: ENA in baseline conditions: from 344.7 7 67.9 to 409.6 7 121.1 (P ¼ 0.02); ENA after amino-acid infusion: from 451. However, the drug-induced increase in the ERPF was less intense and not statistically significant for NIF and NIT after amino-acid infusion. All the drugs studied, with the exception of NIF, were able to provoke a significant decrease in the RVR (dyn Â s Â cm À5 ) (Figure 4 ). In baseline conditions (4a), the mean RVR dropped from 13.7 7 6.7 to 11.4 7 5.5 (P ¼ 0.0025) after ENA, from 14.3 7 5.2 to 10.7 7 2.8 (P ¼ 0.054 NS) after NIF, from 14.4 7 3.6 to 8.1 7 2.7 (P ¼ 0.00003) after NIT and from 22.0 7 7.5 to 13.1 7 3.5 (P ¼ 0.0007) after AML. A similar effect was obtained after amino-acid infusion (4b), and the RVR dropped from 10.9 7 5.7 to 9.4 7 5.3 (P ¼ 0.00009) after ENA, from 10.2 7 3.1 to 8.7 7 3.1 (P ¼ 0.18 NS) after NIF, from 10.1 7 3.4 to 7.7 7 2.3 (P ¼ 0.0016) after NIT, from 15.6 7 5.3 to 12.0 7 3.0 (P ¼ 0.009) after AML.
The FF was significantly reduced after administration of all the drugs except NIF, which induced an increase, albeit not significant, in this parameter both in baseline conditions and after amino-acid infusion ( Figure 5 ). In baseline conditions (5a), the FF went from 0. induced a moderate reduction in the mean blood pressure in all the groups. This blood pressure reduction (delta mean blood pressure) was comparable among groups both in baseline conditions (ENA ¼ 5.2 7 2.1 mmHg, NIF ¼ 4.6 7 1.8 mmHg, NIT ¼ 4.2 7 2.1 mmHg, AML ¼ 4.8 7 2.0 mmHg; ANOVA P ¼ NS) and under hyperfiltration (ENA ¼ 4.7 7 2.0 mmHg, NIF ¼ 4.1 7 2.1 mmHg, NIT ¼ 3.9 7 1.9 mmHg, AML ¼ 4.6 7 2.1 mmHg; ANOVA P ¼ NS)
Discussion
Our findings suggest that the pharmacological effect of AML and NIT is exerted on the postglomerular arterial resistances, as demonstrated by the simultaneous reduction of the RVR and FF. This reduction in the FF, which is observed in both baseline and glomerular hyperfiltration conditions, reflects an imbalance between the GFR and ERPF that may be considered typical of a condition of postglomerular vasodilation. 34 This is supported by a similar haemodynamic effect observed after administration of ENA, which is known to have a vasodilatory effect on the efferent arteriole. [35] [36] [37] [38] On the contrary, vasodilatory drugs that do not reduce the postglomerular resistances, like NIF, in addition to reducing the RVR, trigger an increase in the ERPF without reducing the FF. [39] [40] [41] In fact, the increase in the ERPF is not proportionally greater than that of the GFR, so the FF does not diminish. 42 These haemodynamic changes cannot be attributed either to a hypotensive effect of the drugs, in view of the increase in the ERPF, or to a potential effect on the mesangium, at least as regards ENA, AML and NIT. In fact, drugs that can contract the mesangium can induce a reduction in the glomerular filtration capillary surface and hence in the ultrafiltration coefficient (K f ). 43, 44 It is possible that drugs that reduce the K f can decrease the FF regardless of any vasodilatory effect on the efferent arterioles. It could be that contraction of the mesangium could trigger a dissociation between the GFR and the ERPF, to the advantage of the latter parameter, as a result of a reduction in the glomerular capillary surface assigned to filtration. This does not occur with ACE inhibitors or calcium antagonists, as they tend on the contrary to induce relaxation of the mesangium and an increase in the K f . 34, 35 On the basis of this effect, they would tend to increase, rather than decrease, the FF. Thus, we believe that the reduction in the FF obtained with NIT, AML and ENA must be an expression of a vasodilatory effect on the postglomerular resistances, since it occurs despite the increase in the K f that these drugs could potentially revoke. On the contrary, the increase in the FF observed with NIF, which might well have a causal role in increasing the K f , confirms that this drug cannot trigger vasodilation of the efferent arteriole. [39] [40] [41] The fact that NIT and AML, unlike NIF, can reduce the glomerular hyperfiltration induced by aminoacid infusion is another point in favour of the hypothesis that these two calcium antagonists have a preferential effect on the postglomerular resistances, mimicking that of the ACE inhibitors. The reduction in the GFR provoked by NIT and AML after amino-acid infusion could be attributed to a vasodilatory effect on the efferent arterioles induced by these second-generation dihydropyridinic drugs, while the afferent arterioles, being already maximally dilated by the infusion, could not undergo further drug-induced vasodilation.
In conclusion, the renal haemodynamic effects induced by AML and NIT seem to be more similar to those of ACE inhibitors than to those of other calcium antagonists like NIF. These second-generation dihydropyridinic calcium antagonists seem to exert a vasodilatory effect prevalently on the efferent arterioles, which is thus associated with a reduction in the hydrostatic pressure in the glomerular capillaries. Figure 5 Changes in FF induced by drug administration. Baseline ¼ data obtained without drug and amino-acid administration; drug ¼ data obtained after exposure to the tested drug; amino acids ¼ data obtained after amino-acid infusion; amino-acids and drug ¼ data obtained after amino-acid infusion and drug administration. ENA ¼ enalapril, NIF ¼ nifedipine, NIT ¼ nitrendepine, AML ¼ amlodipine.
